Mobile website
Clinical Research
High-dose interferon is the first choice for postoperative adjuvant therapy of melanoma patients: An observation of 450 samples
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To retrospective study the clinical characteristics of melanoma patients receiving adjuvant therapy after surgery and to evaluate their disease-free survival (DFS) after different treatment options. Methods: Four hundred and fifty patients with malignant melanoma (stageⅠ to Ⅲ), who had received surgery in our center from January 2006 to July 2009, were included in the present study. The patients were from 28 cities, including 239 males and 211 females, with an age range of 12〖KG-*2〗〖DK〗-85 years. After surgery, the patients received different adjuvant therapies, including high-dose interferon treatment (interferon 22 000 000 IU iv. 5 times a week for 4 weeks, or 9 000 000 IU sc. 3 times a week for 11 months), chemotherapy (most cases were treated with dacarbazine or temozolomide; some were treated with cisplatin, paclitaxel and vincristine combination), radiochemotherapy, or radiotherapy (primary tumors or tumor-draining lymph nodes, 40〖KG-*2〗〖DK〗-60 Gy). Results: The surgical options included local resection of the primary lesion, expanded resection of the primary lesion, and extended resection and removal of regional lymph node. The median DFS were 15 months, 24 months and 13 months, respectively. Totally 184 patients did not receive any treatment after surgery, 84 received chemotherapy, 25 received radiochemotherapy, and 2 received radiotherapy; their median DFS were 13 months, 20 months, 29 months and 23 months, respectively. Totally 155 patients received high-dose interferon treatment and the median DFS was not reached. The side effects of chemotherapy included gastrointestinal side effects, bone marrow suppression and liver damage. The side effects of high-dose interferon included leukopenia, fever, fatigue, increased aminotransferase and anorexia. The incidences of severe leukopenia and increased aminotransferase (reaching 3 or 4 degree) were 15% and 10%, respectively. All patients returned to normal after symptomatic treatment. Conclusion:Surgical resection and adjuvant therapy strategy are extremely important for DFS of patients with malignant melanoma in stageⅠ to Ⅲ. The best DFS can be obtained in malignant melanoma patients who receive high-dose interferon therapy after surgery, with better safety.
Keywords:
Project Supported:
Clc Number:
